...MK-7264) met the primary endpoint in adult patients with treatment-refractory or unexplained chronic cough. The P2X3... ...“CTFH Latest to Partner with Insilico” ). Targets IL-23 - Interleukin-23 JAK-1 - Janus kinase-1 P2X3... ...3 TERT - Telomerase reverse transcriptase
Merck & Co. Inc.
Sage Therapeutics Inc.
Purinergic receptor P2X ligand-gated ion channel 3 (P2X3)
...million, are Jefferies, Cowen, Guggenheim, Baird and Bloom Burton. The company's BLU-5937, a small molecule P2X3... ...diagnosed with and at risk for Type II diabetes. Targets: ALOX12 (12-LOX) - Arachidonate 12-lipoxygenase; P2X3...
...inhibitor. A third program highlighted by Merck was gefapixant (MK-7264), a purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor antagonist. The P2X3... ...around CEO succession timing, Merck said at the time. Targets: DPP-4 (CD26) - dipeptidyl peptidase-4; P2X3...
...cough. Bellus Health has exclusive, worldwide rights to the selective small molecule antagonist of the purinergic receptor P2X ligand-gated ion channel 3 (P2X3)... ...receptor from the Neomed Institute (Montreal, Quebec). Bellus Health Inc. (TSX:BLU), Laval, Quebec
Bellus Health Inc.
P2X3Purinergic receptor P2X ligand-gated ion channel 3 (P2X3)...
...in clinical and commercialization milestones for candidates in Afferent’s pipeline, including AF-219 . AF-219, a purinergic receptor P2X ligand-gated ion channel 3 (P2X3)... ...exclusive, worldwide rights from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) to develop and commercialize the pharma’s P2X3...